Method and apparatus for providing treatment-related prediction information of alzheimer's disease

The method analyzes brain scan images to calculate scores based on tau protein accumulation, providing predictive information for Alzheimer's disease treatment, addressing the challenge of determining treatment suitability and timing, and improving treatment outcomes.

WO2024242246A1PCT designated stage expired Publication Date: 2024-11-28NEUROXT INC
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2023/016959
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-24
Filing Date
2023-10-30
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Current methods fail to accurately predict the suitability and timing of Alzheimer's disease treatment for individual patients based on tau protein accumulation in the brain, making it difficult to determine the effectiveness of specific drugs and the optimal treatment time.

Method used

A method and device that analyze brain scan images to calculate scores related to treatment need and efficacy by assessing tau protein accumulation in specific brain regions, providing predictive information on when treatment is most effective and determining the golden time for treatment.

Benefits of technology

Enables personalized treatment strategies by accurately predicting the progression of Alzheimer's disease and determining the appropriate treatment timing, improving treatment outcomes for patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2023016959_28112024_PF_FP_ABST
    Figure KR2023016959_28112024_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure provides a method for providing treatment-related prediction information of Alzheimer's disease. The method for providing treatment-related prediction information comprises the steps of: receiving a brain scan image of a subject; determining the amount of tau protein accumulation in a first region of the subject's brain on the basis of the scan image; and calculating a first score associated with the need for treatment of Alzheimer's disease in the subject on the basis of the amount of tau protein accumulation in the first region of the subject's brain.
Need to check novelty before this filing date? Find Prior Art

Description

Method and device for providing predictive information related to treatment of Alzheimer's disease

[0001] The present disclosure relates to a method and device for providing treatment-related prediction information for Alzheimer's disease, and more particularly, to a method and device for performing treatment-related prediction for Alzheimer's disease based on the amount of tau protein accumulation in each region of a subject's brain.

[0002] Alzheimer's disease is a neurodegenerative disease and the most common cause of dementia in the elderly. The exact cause of Alzheimer's disease remains unknown, and various hypotheses exist regarding its cause.

[0003] Meanwhile, when deciding whether or how to treat a specific disease, both the individual patient's need for treatment and the benefits of the proposed treatment must be considered. However, existing clinical trials or approvals from relevant institutions often fail to accurately predict whether a particular drug is necessary or beneficial for a specific patient. For example, even though the US FDA has approved a drug, concluding that its benefits outweigh its risks and that the drug offers a public health benefit, it is extremely difficult to determine whether an individual patient is suitable for the drug based on specific criteria or predictive methods.

[0004] In particular, in the treatment of Alzheimer's disease, treatment methods and strategies vary depending on the individual patient's need for treatment or the effective duration of treatment. Therefore, it is necessary to identify the golden time for treatment. However, using existing technology, it is extremely difficult to determine the golden time for treatment for each individual patient.

[0005] The present disclosure provides a method for providing predictive information related to treatment of Alzheimer's disease, a computer program stored in a recording medium, and a device (system) to solve the above-described problems.

[0006] The present disclosure can be implemented in various ways, including as a method, a system (device), or a computer program stored on a readable storage medium.

[0007] A method for providing treatment-related prediction information for Alzheimer's disease, executed by at least one processor according to one embodiment of the present disclosure, comprises the steps of: receiving a brain scan image of a subject; determining a tau protein accumulation amount in a first region of the subject's brain based on the scan image; and calculating a first score associated with the subject's need for Alzheimer's disease treatment based on the tau protein accumulation amount in the first region of the subject's brain.

[0008] In one embodiment of the present disclosure, the method further comprises the step of determining the amount of tau protein accumulation in a second region of the brain of the subject based on the scan image, and the step of calculating a second score associated with the efficacy of treating Alzheimer's disease of the subject based on the amount of tau protein accumulation in the second region, wherein the first region and the second region are different regions.

[0009] In one embodiment of the present disclosure, the first score is maintained or increased as the amount of tau protein accumulation in the first region of the subject's brain increases, and the second score is maintained or decreased as the amount of tau protein accumulation in the second region of the subject's brain increases.

[0010] In one embodiment of the present disclosure, the method further comprises the step of calculating a comprehensive score associated with treatment of Alzheimer's disease of the subject based on the first score and the second score.

[0011] In one embodiment of the present disclosure, the method further comprises a step of determining whether to treat or what type of treatment is required for the subject's Alzheimer's disease, based on at least one of the first score, the second score, or the overall score.

[0012] In one embodiment of the present disclosure, the method further includes a step of determining the start time of the golden time for treatment of Alzheimer's disease of the subject based on the first score.

[0013] In one embodiment of the present disclosure, the method further includes a step of predicting the time remaining until the start of the treatment golden time for Alzheimer's disease of the subject based on the determined start time of the treatment golden time.

[0014] In one embodiment of the present disclosure, the step of calculating the first score includes the step of calculating a first time interval between a first time corresponding to the amount of tau protein accumulated in the first region of the subject's brain and a second time at which the amount of tau protein accumulated is a first threshold value, on a first path representing a predicted value of the amount of tau protein accumulated in the first region over time, and the step of calculating the first score based on the first time interval.

[0015] In one embodiment of the present disclosure, the first pathway is determined based on a data set associated with the amount of tau protein accumulation in a first region of the brain over time in each of the subject and a plurality of other subjects.

[0016] In one embodiment of the present disclosure, the method further includes a step of determining the end point of the golden time for treating Alzheimer's disease based on the second score.

[0017] In one embodiment of the present disclosure, the method further includes a step of predicting the time remaining until the end of the treatment golden time for Alzheimer's disease of the subject based on the end point of the determined treatment golden time.

[0018] In one embodiment of the present disclosure, the step of calculating the second score includes the step of calculating a second time interval between a third time corresponding to the amount of tau protein accumulated in the second region of the subject's brain and a fourth time at which the amount of tau protein accumulated is a second threshold value, on a second path representing a predicted value of the amount of tau protein accumulated in the second region over time, and the step of calculating the second score based on the second time interval.

[0019] In one embodiment of the present disclosure, the second pathway is determined based on a data set associated with the amount of tau protein accumulation in a second region of the brain over time in each of the subject and a plurality of other subjects.

[0020] In one embodiment of the present disclosure, the subject is a patient who is determined to have accumulated beta-amyloid protein (Aβ) in the subject's brain above a predetermined threshold.

[0021] In one embodiment of the present disclosure, the first region is the entorhinal cortex (EC) region.

[0022] In one embodiment of the present disclosure, the second region is the inferior temporal gyrus (ITG) region.

[0023] In one embodiment of the present disclosure, the method further comprises a step of identifying the subject as being within the golden time for responding to amyloid modulation therapy as a treatment for Alzheimer's disease, in response to determining that the composite score is greater than a predetermined third threshold.

[0024] In one embodiment of the present disclosure, the method further comprises identifying the subject as likely to respond to an Alzheimer's disease prevention therapy in response to determining that the first score is less than a predetermined first threshold.

[0025] In one embodiment of the present disclosure, the method further comprises identifying the subject as likely to respond to combination therapy comprising amyloid modulation therapy and tau modulation therapy as a treatment for Alzheimer's disease, in response to determining that the second score is less than a predetermined second threshold.

[0026] A computer program stored in a computer-readable recording medium is provided for executing a method for providing treatment-related prediction information for Alzheimer's disease according to one embodiment of the present disclosure on a computer.

[0027] In one embodiment of the present disclosure, a device comprises a communication module, a memory, and at least one processor connected to the memory and configured to execute at least one computer-readable program contained in the memory, wherein the at least one program comprises instructions for receiving a brain scan image of a subject, determining an amount of tau protein accumulation in a first region of the subject's brain based on the scan image, and calculating a first score associated with a need for Alzheimer's disease treatment of the subject based on the amount of tau protein accumulation in the first region of the subject's brain.

[0028] According to various embodiments of the present disclosure, the suitability of Alzheimer's disease treatment at the present time can be determined by providing an individual patient with predictive information based on the present time regarding the need for or efficacy of Alzheimer's disease treatment.

[0029] According to various embodiments of the present disclosure, by predicting the degree of disease progression and efficacy of an individual patient over time based on the general progression trajectory of Alzheimer's disease, it is possible to determine when or how long treatment for Alzheimer's disease will be appropriate, and to assist patients and physicians in developing treatment strategies.

[0030] The effects of the present disclosure are not limited to the effects mentioned above, and other effects not mentioned can be clearly understood by a person having ordinary skill in the art to which the present disclosure belongs (referred to as “one skilled in the art”) from the description of the claims.

[0031] Embodiments of the present disclosure will be described below with reference to the accompanying drawings, wherein like reference numerals represent similar elements, but are not limited thereto.

[0032] FIG. 1 is a diagram illustrating an example of calculating a score associated with Alzheimer's disease treatment based on a brain scan image of a subject according to one embodiment of the present disclosure.

[0033] FIG. 2 is a schematic diagram showing a configuration in which an information processing system is connected to enable communication with a plurality of user terminals in order to provide a prediction service related to treatment of Alzheimer's disease according to one embodiment of the present disclosure.

[0034] FIG. 3 is a block diagram showing the internal configuration of a user terminal and an information processing system according to one embodiment of the present disclosure.

[0035] FIG. 4 is a block diagram showing the internal configuration of a processor according to one embodiment of the present disclosure.

[0036] FIG. 5 is a diagram showing an example of a predicted value graph of tau protein accumulation in the first region and the second region over time according to one embodiment of the present disclosure.

[0037] FIG. 6 is a diagram illustrating an example of a graph showing necessity scores and efficacy scores over time according to one embodiment of the present disclosure.

[0038] FIG. 7 is a diagram showing an example of a graph of predicted values ​​of a comprehensive score over time according to one embodiment of the present disclosure.

[0039] FIG. 8 is a flowchart illustrating a method for providing prediction information related to treatment of Alzheimer's disease according to one embodiment of the present disclosure.

[0040] Hereinafter, specific details for implementing the present disclosure will be described in detail with reference to the attached drawings. However, in the following description, specific descriptions of widely known functions or configurations will be omitted if they may unnecessarily obscure the gist of the present disclosure.

[0041] In the attached drawings, identical or corresponding components are assigned the same reference numerals. Furthermore, in the description of the embodiments below, duplicate descriptions of identical or corresponding components may be omitted. However, even if a description of a component is omitted, it is not intended that such component is not included in any embodiment.

[0042] The advantages and features of the disclosed embodiments, and methods for achieving them, will become clearer with reference to the embodiments described below, along with the accompanying drawings. However, the present disclosure is not limited to the embodiments disclosed below and may be implemented in various different forms. These embodiments are provided solely to ensure the completeness of the disclosure and to fully inform those skilled in the art of the scope of the invention.

[0043] The terms used in this specification will be briefly explained, followed by a detailed description of the disclosed embodiments. The terms used in this specification have been selected from widely used, common terms, taking into account the functions of the present disclosure. However, these terms may vary depending on the intentions of engineers working in the relevant fields, precedents, the emergence of new technologies, etc. Furthermore, in certain cases, terms may be arbitrarily selected by the applicant, and in such cases, their meanings will be described in detail in the relevant description of the invention. Therefore, the terms used in this disclosure should not be defined simply as names of terms, but rather based on their meanings and the overall content of the present disclosure.

[0044] In this specification, singular expressions include plural expressions unless the context clearly indicates otherwise. Furthermore, plural expressions include singular expressions unless the context clearly indicates otherwise. When a part of the specification is said to include a component, this does not exclude other components, but rather implies that other components may be included, unless otherwise specifically stated.

[0045] Also, the term 'module' or 'part' used in the specification means a software or hardware component, and the 'module' or 'part' performs certain roles. However, the 'module' or 'part' is not limited to software or hardware. The 'module' or 'part' may be configured to reside on an addressable storage medium and may be configured to execute one or more processors. Thus, as an example, the 'module' or 'part' may include at least one of components such as software components, object-oriented software components, class components, and task components, processes, functions, attributes, procedures, subroutines, segments of program code, drivers, firmware, microcode, circuits, data, databases, data structures, tables, arrays, or variables. The functionality provided within the components and 'modules' or 'parts' may be combined into a smaller number of components and 'modules' or 'parts', or further separated into additional components and 'modules' or 'parts'.

[0046] According to one embodiment of the present disclosure, a 'module' or 'unit' may be implemented as a processor and a memory. 'Processor' should be broadly construed to include a general-purpose processor, a central processing unit (CPU), a microprocessor, a digital signal processor (DSP), a controller, a microcontroller, a state machine, and the like. In some circumstances, a 'processor' may also refer to an application-specific integrated circuit (ASIC), a programmable logic device (PLD), a field-programmable gate array (FPGA), and the like. A 'processor' may also refer to a combination of processing devices, such as, for example, a combination of a DSP and a microprocessor, a combination of multiple microprocessors, a combination of one or more microprocessors in conjunction with a DSP core, or any other such combination of configurations. In addition, 'memory' should be broadly construed to include any electronic component capable of storing electronic information. 'Memory' may refer to various types of processor-readable media, such as random access memory (RAM), read-only memory (ROM), non-volatile random access memory (NVRAM), programmable read-only memory (PROM), erasable programmable read-only memory (EPROM), electrically erasable PROM (EEPROM), flash memory, magnetic or optical data storage, registers, etc. Memory is said to be in electronic communication with the processor if the processor can read information from, and / or write information to, the memory. Memory integrated in a processor is in electronic communication with the processor.

[0047] In the present disclosure, the term "subject" may refer to a patient or subject for whom a prediction regarding treatment of Alzheimer's disease according to the present disclosure is to be made. For example, the "subject" may be a patient determined to have accumulated beta-amyloid protein (Aβ) in the subject's brain above a predetermined threshold.

[0048] In this disclosure, 'efficacy' may refer to the ability of a particular drug, treatment, or the like to treat or engage in a targeted beneficial effect or outcome, such as curing a particular disease or reducing or eliminating symptoms of a particular disease.

[0049] In this disclosure, the "golden time for treatment" may refer to the optimal time for treating a disease. For example, the "golden time for treatment" may refer to the stage or period during the course of a disease that is likely to have the highest rate of treatment success.

[0050] FIG. 1 is a diagram illustrating an example of calculating scores (132, 142, 152) associated with Alzheimer's disease treatment based on a brain scan image (110) of a subject according to one embodiment of the present disclosure. The brain scan image (110) of the subject may be captured in various ways, such as MRI (Magnetic Resonance Imaging), PET scan (Positron Emission Tomography Scans), fMRI (Functional Magnetic Resonance Imaging), CT scan (Computed Tomography Scans), SPECT (Single Photon Emission Computed Tomography), Amyloid PET scan, Tau PET scan, etc., and is not limited to the listed methods. The brain scan image (110) is illustrated as a single image, but is not limited thereto, and may include a plurality of images and / or images, etc.

[0051] The amount of tau protein accumulation (120) in the brain of a subject can be determined / predicted based on a brain scan image (110). In one embodiment, the amount of tau protein accumulation in a first region of the brain of the subject and the amount of tau protein accumulation in a second region of the brain of the subject, which is different from the first region of the brain of the subject, can be determined / predicted based on the brain scan image (110).

[0052] In one embodiment, the first region in which tau protein accumulation is determined may be the entorhinal cortex (EC) region, and the second region may be the inferior temporal gyrus (ITG) region. The amount of tau protein accumulation in the entorhinal cortex region may be determined / predicted by quantifying the relative amount of tau protein accumulation within one or more entorhinal cortex regions.

[0053] Alternatively, the specific locations of the first and / or second regions can be determined / predicted by calculating the goodness of fit (GOF) between a region map showing the degree of tau protein accumulation in the brains of multiple subjects and a connectivity map (e.g., a structural connectivity map and / or a functional connectivity map) between one or more regions in the brains of multiple subjects. In one embodiment, the goodness of fit between the region map and the connectivity map can be calculated by an artificial intelligence model.

[0054] In one embodiment, based on the determined tau protein accumulation amount (120), a first score (132) associated with the subject's need for Alzheimer's disease treatment and / or a second score (142) associated with the efficacy of the treatment may be calculated. For example, the first score (132) may be calculated based on the tau protein accumulation amount in the first region (112) and the first graph (130), and the second score (142) may be calculated based on the tau protein accumulation amount in the second region (114) and the second graph (140). The specific process of calculating the first score (132) and the second score (142) will be described in detail below with reference to FIGS. 5 and 6 .

[0055] Thereafter, based on the calculated first score (132) and second score (142), a comprehensive score (152) on a third graph (150) associated with the treatment of the subject's Alzheimer's disease can be calculated. The specific process of calculating the comprehensive score (152) will be described in detail later using FIG. 7.

[0056] FIG. 2 is a schematic diagram showing a configuration in which an information processing system (230) is connected to a plurality of user terminals (210_1, 210_2, 210_3) so as to be able to communicate with each other in order to provide a prediction service related to treatment of Alzheimer's disease according to one embodiment of the present disclosure. The information processing system (230) may include system(s) capable of providing a prediction service related to treatment of Alzheimer's disease. In one embodiment, the information processing system (230) may include one or more server devices and / or databases capable of storing, providing, and executing computer-executable programs (e.g., downloadable applications) and data related to the prediction service related to treatment of Alzheimer's disease, or one or more distributed computing devices and / or distributed databases based on cloud computing services.

[0057] The treatment-related prediction service for Alzheimer's disease provided by the information processing system (230) can be provided to users through applications installed on each of a plurality of user terminals (210_1, 210_2, 210_3).

[0058] A plurality of user terminals (210_1, 210_2, 210_3) can communicate with an information processing system (230) via a network (220). The network (220) can be configured to enable communication between the plurality of user terminals (210_1, 210_2, 210_3) and the information processing system (230). Depending on the installation environment, the network (220) can be configured as a wired network such as Ethernet, a wired home network (Power Line Communication), a telephone line communication device, and RS-serial communication, a wireless network such as a mobile communication network, WLAN (Wireless LAN), Wi-Fi, Bluetooth, and ZigBee, or a combination thereof. The communication method is not limited, and may include not only a communication method utilizing a communication network (e.g., a mobile communication network, wired Internet, wireless Internet, broadcasting network, satellite network, etc.) that the network (220) may include, but also short-range wireless communication between user terminals (210_1, 210_2, 210_3).

[0059] For example, multiple user terminals (210_1, 210_2, 210_3) can transmit requests to the information processing system (230) via the network (220), and the information processing system (230) can receive the requests and transmit responses corresponding to the requests to the multiple user terminals (210_1, 210_2, 210_3). For example, when a user terminal (210_1) transmits a brain scan image of a subject and a request for prediction related to treatment of Alzheimer's disease to the information processing system (230) (request), the information processing system (230) can transmit scores related to the necessity or efficacy of treatment of Alzheimer's disease, information related to the golden time for treatment, etc. to the user terminal (210_1) based on the brain scan image (response).

[0060] In FIG. 2, a mobile phone terminal (210_1), a tablet terminal (210_2), and a PC terminal (210_3) are illustrated as examples of user terminals, but are not limited thereto, and the user terminals (210_1, 210_2, 210_3) may be any computing device capable of wired and / or wireless communication and capable of installing and executing prediction applications related to treatment of Alzheimer's disease. For example, the user terminals may include medical devices, smartphones, mobile phones, navigation devices, computers, laptops, digital broadcasting terminals, PDAs (Personal Digital Assistants), PMPs (Portable Multimedia Players), tablet PCs, game consoles, wearable devices, IoT (Internet of Things) devices, VR (virtual reality) devices, AR (augmented reality) devices, etc. In addition, although FIG. 2 illustrates three user terminals (210_1, 210_2, 210_3) communicating with the information processing system (230) via the network (220), this is not limited thereto, and a different number of user terminals may be configured to communicate with the information processing system (230) via the network (220).

[0061] FIG. 3 is a block diagram showing the internal configuration of a user terminal (210) and an information processing system (230) according to one embodiment of the present disclosure. The user terminal (210) may refer to any computing device capable of executing a prediction application related to treatment of Alzheimer's disease and capable of wired / wireless communication, and may include, for example, a mobile phone terminal (210_1), a tablet terminal (210_2), a PC terminal (210_3) of FIG. 2. As illustrated, the user terminal (210) may include a memory (312), a processor (314), a communication module (316), and an input / output interface (318). Similarly, the information processing system (230) may include a memory (332), a processor (334), a communication module (336), and an input / output interface (338). As illustrated in FIG. 3, the user terminal (210) and the information processing system (230) may be configured to communicate information and / or data via a network (220) using respective communication modules (316, 336). In addition, the input / output device (320) may be configured to input information and / or data to the user terminal (210) or output information and / or data generated from the user terminal (210) via the input / output interface (318).

[0062] The memory (312, 332) may include any non-transitory computer-readable recording medium. According to one embodiment, the memory (312, 332) may include a permanent mass storage device such as a read-only memory (ROM), a disk drive, a solid-state drive (SSD), or flash memory. As another example, a permanent mass storage device such as a ROM, an SSD, a flash memory, or a disk drive may be included in the user terminal (210) or the information processing system (230) as a separate permanent storage device distinct from the memory. In addition, the memory (312, 332) may store an operating system and at least one program code (e.g., code for a prediction application related to the treatment of Alzheimer's disease, etc.).

[0063] These software components may be loaded from a computer-readable recording medium separate from the memory (312, 332). This separate computer-readable recording medium may include a recording medium directly connectable to the user terminal (210) and the information processing system (230), and may include, for example, a computer-readable recording medium such as a floppy drive, a disk, a tape, a DVD / CD-ROM drive, a memory card, etc. As another example, the software components may be loaded into the memory (312, 332) through a communication module (316, 336) other than a computer-readable recording medium. For example, at least one program may be loaded into the memory (312, 332) based on a computer program (e.g., a prediction application related to the treatment of Alzheimer's disease, etc.) that is installed by files provided by developers or a file distribution system that distributes installation files of applications through a network (220).

[0064] The processor (314, 334) may be configured to process instructions of a computer program by performing basic arithmetic, logic, and input / output operations. Instructions may be provided to the processor (314, 334) by a memory (312, 332) or a communication module (316, 336). For example, the processor (314, 334) may be configured to execute instructions received according to program code stored in a storage device such as the memory (312, 332).

[0065] The communication modules (316, 336) may provide a configuration or function for the user terminal (210) and the information processing system (230) to communicate with each other via the network (220), and may provide a configuration or function for the user terminal (210) and / or the information processing system (230) to communicate with another user terminal or another system (e.g., a separate cloud system, etc.). For example, a request or data generated by the processor (314) of the user terminal (210) according to a program code stored in a recording device such as a memory (312) may be transmitted to the information processing system (230) via the network (220) under the control of the communication module (316). Conversely, a control signal or command provided under the control of the processor (334) of the information processing system (230) may be received by the user terminal (210) via the communication module (316) of the user terminal (210) via the communication module (336) and the network (220).

[0066] The input / output interface (318) may be a means for interfacing with an input / output device (320). As an example, the input device may include a device such as a camera, a keyboard, a microphone, a mouse, etc., including an audio sensor and / or an image sensor, and the output device may include a device such as a display, a speaker, a haptic feedback device, etc. As another example, the input / output interface (318) may be a means for interfacing with a device that has a configuration or function integrated into one for performing input and output, such as a touch screen. In FIG. 3, the input / output device (320) is illustrated as not being included in the user terminal (210), but is not limited thereto and may be configured as a single device with the user terminal (210). In addition, the input / output interface (338) of the information processing system (230) may be a means for interfacing with a device (not shown) for input or output that is connected to the information processing system (230) or that the information processing system (230) may include. In FIG. 3, the input / output interface (318, 338) is illustrated as an element configured separately from the processor (314, 334), but is not limited thereto, and the input / output interface (318, 338) may be configured to be included in the processor (314, 334).

[0067] The user terminal (210) and the information processing system (230) may include more components than those shown in FIG. 3. However, it is not necessary to explicitly illustrate most of the conventional technical components. In one embodiment, the user terminal (210) may be implemented to include at least some of the input / output devices (320) described above. In addition, the user terminal (210) may further include other components such as a transceiver, a Global Positioning System (GPS) module, a camera, various sensors, a database, etc. For example, if the user terminal (210) is a smartphone, it may include components that a smartphone generally includes, and for example, various components such as an acceleration sensor, a gyro sensor, a microphone module, a camera module, various physical buttons, buttons using a touch panel, input / output ports, and a vibrator for vibration may be implemented to be further included in the user terminal (210).

[0068] According to one embodiment, the processor (314) of the user terminal (210) may be configured to operate an application or a web browser application that provides a prediction service related to the treatment of Alzheimer's disease. At this time, program code associated with the application may be loaded into the memory (312) of the user terminal (210). While the application is operating, the processor (314) of the user terminal (210) may receive information and / or data provided from the input / output device (320) through the input / output interface (318) or may receive information and / or data from the information processing system (230) through the communication module (316), and may process the received information and / or data and store it in the memory (312). In addition, such information and / or data may be provided to the information processing system (230) through the communication module (316).

[0069] While the application is running, the processor (314) can receive voice data, text, images, videos, etc. input or selected through input devices such as a camera, microphone, touch screen, keyboard, audio sensor, and / or image sensor connected to the input / output interface (318), and can store the received voice data, text, images, and / or videos, etc. in the memory (312) or provide them to the information processing system (230) through the communication module (316) and the network (220).

[0070] The processor (314) of the user terminal (210) can output information and / or data by transmitting the information and / or data to an input / output device (320) through an input / output interface (318). For example, the processor (314) of the user terminal (210) can output the processed information and / or data through an output device (320), such as a display output capable device (e.g., a touch screen, a display, etc.) or a voice output capable device (e.g., a speaker).

[0071] The processor (334) of the information processing system (230) may be configured to manage, process, and / or store information and / or data received from multiple user terminals (210) and / or multiple external systems. Information and / or data processed by the processor (334) may be provided to the user terminal (210) via a communication module (336) and a network (220).

[0072] FIG. 4 is a block diagram illustrating the internal configuration of a processor (400) according to one embodiment of the present disclosure. As illustrated, the processor (400) (e.g., the processor (314) of the user terminal of FIG. 3 or the processor (334) of the information processing system) may include a tau protein accumulation amount determination unit (410), a score calculation unit (420), a treatment determination unit (430), a golden time determination unit (440), and the like.

[0073] The tau protein accumulation determination unit (410) can determine / predict the tau protein accumulation amount in a first region of the subject's brain based on a brain scan image of the subject. Additionally, the tau protein accumulation determination unit (410) can determine / predict the tau protein accumulation amount in a second region of the subject's brain based on the scan image. In this case, the first region and the second region may be different regions. For example, the first region may be the entorhinal cortex (EC) region, and the second region may be the inferior temporal gyrus (ITG) region.

[0074] The score calculation unit (420) may calculate a first score associated with the need for Alzheimer's disease treatment of the subject based on the tau protein accumulation amount in the first region of the brain of the subject determined by the tau protein accumulation amount determination unit (410). In one embodiment, the score calculation unit (420) may calculate the first score based on a first time interval between a first time corresponding to the tau protein accumulation amount in the first region of the brain of the subject and a second time corresponding to a first threshold value of the tau protein accumulation amount, on a first path representing a predicted value of the tau protein accumulation amount in the first region of the brain of the subject over time. In this case, the first path may be determined / estimated / generated based on a data set associated with the tau protein accumulation amount in the first region of the brain over time of each of the subject and / or a plurality of other subjects.

[0075] The score calculation unit (420) may calculate a second score associated with the efficacy of Alzheimer's disease treatment of the subject based on the tau protein accumulation amount of the second region determined by the tau protein accumulation amount determination unit (410). In one embodiment, the score calculation unit (420) may calculate the second score based on a second time interval between a third time corresponding to the tau protein accumulation amount of the second region of the brain of the subject and a fourth time corresponding to a second threshold value of tau protein accumulation amount, on a second path representing a predicted value of the tau protein accumulation amount of the second region of the brain of the subject over time. In this case, the second path may be determined / estimated / generated based on a data set associated with the tau protein accumulation amount of the second region of the brain over time of each of the subject and / or a plurality of other subjects.

[0076] In one embodiment, the first score calculated by the score calculation unit (420) may be maintained or increased as the amount of tau protein accumulation in the first region of the subject's brain increases, and the second score may be maintained or decreased as the amount of tau protein accumulation in the second region of the subject's brain increases. Based on the first score and the second score, the score calculation unit (420) may calculate a comprehensive score associated with the treatment of the subject's Alzheimer's disease.

[0077] The treatment decision unit (430) can determine / predict at least one of whether to treat or the type of treatment associated with the subject's Alzheimer's disease based on at least one of the first score, the second score, or the comprehensive score calculated by the score calculation unit (420).

[0078] In one embodiment, the treatment decision unit (430) can identify the subject as being within the golden time for responding to amyloid modulation therapy as a treatment for Alzheimer's disease in response to determining that the composite score is greater than a predetermined third threshold (i.e., comprising high need and high efficacy and a period of time for which the condition is maintained). In another embodiment, the treatment decision unit (430) can identify the subject as being likely to respond to Alzheimer's disease prevention therapy in response to determining that the first score is less than a predetermined first threshold (i.e., comprising low need and high efficacy). Here, the Alzheimer's disease prevention therapy may comprise administration of an amyloid (Aβ) vaccine and / or a tau vaccine. In yet another embodiment, the treatment decision unit (430) can identify the subject as being likely to respond to combination therapy comprising amyloid modulation therapy and tau modulation therapy as a treatment for Alzheimer's disease in response to determining that the second score is less than a predetermined second threshold (comprising high need and low efficacy).

[0079] In one embodiment, if the first score is less than a predetermined first threshold, the golden time determination unit (440) may determine / predict the start time of the golden time for treatment of the subject's Alzheimer's disease based on the first score calculated by the score calculation unit (420). Thereafter, based on the determined start time of the golden time for treatment, the remaining time until the start of the golden time for treatment of the subject's Alzheimer's disease may be predicted.

[0080] In one embodiment, the golden time determination unit (440) can determine / predict the end point of the golden time for treatment of Alzheimer's disease based on the second score calculated by the score calculation unit (420). Thereafter, the golden time determination unit (440) can predict the time remaining until the end point of the golden time for treatment of Alzheimer's disease of the subject based on the determined end point of the golden time for treatment.

[0081] The internal configuration of the processor (400) illustrated in FIG. 4 is merely an example, and in some embodiments, other configurations may be additionally included in addition to the illustrated internal configuration, and some configurations may be omitted. For example, if the processor (400) is the processor (334) of the information processing system of FIG. 3 and some of the above internal configurations are omitted, the processor (314) of the user terminal may be configured to perform the functions of some of the omitted internal configurations. In addition, although the internal configuration of the processor (400) in FIG. 4 is described by dividing it by function, it does not necessarily mean that it is physically separated. The tau protein accumulation amount determination unit (410), the score calculation unit (420), the treatment determination unit (430), and the golden time determination unit (440) are described separately, but this is to help understanding of the invention and is not limited thereto.

[0082] FIG. 5 is a diagram illustrating an example of a graph (500) of predicted values ​​of tau protein accumulation in a first region and a second region over time according to one embodiment of the present disclosure. In one example, a first path (510) of the graph (500) illustrates an example of predicted values ​​of tau protein accumulation in a first region of a subject's brain over time, and a second path (520) illustrates an example of predicted values ​​of tau protein accumulation in a second region of a subject's brain over time.

[0083] Each of the first pathway (510) and the second pathway (520) can be determined / estimated / generated based on a data set associated with the amount of tau protein accumulation in each of the first and second brain regions over time for each of the subject and / or each of a plurality of other subjects. For example, each of the first pathway (510) and the second pathway (520) can be determined by standardizing and averaging the amount of tau protein accumulation over time for each of the plurality of subjects.

[0084] In one embodiment, the plurality of subjects that form the basis for determining the first path (510) and the second path (520) may be selected based on at least one of the subject's medical information, such as the subject's age, gender, race, height, weight, body mass index (BMI), blood pressure level, or smoking status. Through this configuration, the accuracy of the predicted value of the subject's tau protein accumulation over time may be improved by using data from other subjects with similar medical characteristics to the subject. Additionally or alternatively, the first path (510) and the second path (520) may be standard models generated based on big data associated with the tau protein accumulation in each of the first and second brain regions of the plurality of subjects.

[0085] A first threshold (518) of tau protein accumulation in the first region may be set on the first path (510). In one embodiment, the first threshold (518) may be a tau protein accumulation amount that can cause tau protein propagation to surrounding regions of the first region by interacting with amyloid protein and tau protein in the first region (e.g., entorhinal cortex region). The second time (t2) of the graph (500) may refer to a time at which the tau protein accumulation in the first region on the first path (510) reaches the first threshold (518).

[0086] A second threshold (528) for tau protein accumulation in the second region may be set in the second path (520). In one embodiment, the second threshold (528) may correspond to the amount of tau protein accumulation at which amyloid protein and tau protein in the second region (e.g., inferior temporal gyrus region) interact to cause tau protein propagation to a wide area. The fourth time (t4) of the graph (500) may refer to the time at which the tau protein accumulation in the second region on the second path (520) reaches the second threshold (528).

[0087] In one embodiment, the first threshold value (518) and / or the second threshold value (528) may be determined differently for each subject based on at least one of the subject's medical information. In another embodiment, the first threshold value (518) and / or the second threshold value (528) may be set based on a control data set that includes data on tau protein accumulation in a control group in which tau protein accumulation is at a normal level or in which no symptoms of Alzheimer's disease are present.

[0088] In the graph (500), each of the first accumulation (512) and the fourth accumulation (522) represents a predicted amount of tau protein accumulation in the first region and the second region, respectively, at a first time (t1), which is any time prior to a second time (t2). Each of the second accumulation (514) and the fifth accumulation (524) may represent a predicted amount of tau protein accumulation in the first region and the second region, respectively, at a third time (t3), which is any time between the second time (t2) and the fourth time (t4). Each of the third accumulation (516) and the sixth accumulation (526) may represent a predicted amount of tau protein accumulation in the first region and the second region, respectively, at a fifth time (t5), which is any time after the fourth time (t4). Each of the first to fifth times (t1, t2, t3, t4, t5) illustrated in FIG. 5 is also illustrated and described in the same manner in FIG. 6 and FIG. 7, which will be described later.

[0089] FIG. 6 is a diagram illustrating an example of a graph (600) showing necessity scores and efficacy scores over time according to one embodiment of the present disclosure. The first curve (610) illustrates an example of a necessity score (i.e., a first score) associated with a subject's need for Alzheimer's disease treatment. The second curve (620) illustrates an example of an efficacy score (i.e., a second score) associated with the efficacy of Alzheimer's disease treatment for the subject.

[0090] The need score may be maintained or increased as the amount of tau protein accumulation in the first region of the subject's brain increases, and the efficacy score may be maintained or decreased as the amount of tau protein accumulation in the second region of the subject's brain increases. For example, a first curve (610) may be predefined such that the need score increases rapidly and is then maintained at a second time (t2) when the amount of tau protein accumulation in the first region reaches the first threshold (518) of FIG. 5, as illustrated. Additionally, a second curve (620) may be predefined such that the efficacy score decreases and is then maintained at a fourth time (t4) when the amount of tau protein accumulation in the second region reaches the second threshold (528) of FIG. 5.

[0091] The first curve (610) may be associated with / correspond to the first path (510) of FIG. 5. For example, each of the first score (612), the second score (614), the third score (616), and the fourth score (618) on the first curve (610) corresponds, in order, to the first accumulation (512), the second accumulation (514), the third accumulation (516), and the first threshold (518) on the first path (510) of FIG. 5. For example, if the tau protein accumulation in the first region of the subject's brain corresponds to the first accumulation (512), the subject's need score may be the first score (612).

[0092] The second curve (620) may be associated with / correspond to the second path (520) of FIG. 5. For example, each of the fifth score (622), the sixth score (624), the seventh score (626), and the eighth score (628) on the second curve (620) corresponds, in order, to the fourth accumulation (522), the fifth accumulation (524), the sixth accumulation (526), ​​and the second threshold (528) on the second path (520) of FIG. 5. For example, if the tau protein accumulation in the second region of the subject's brain corresponds to the fourth accumulation (522), the subject's efficacy score may be the fifth score (622).

[0093] In one embodiment, a subject's need score and / or efficacy score may be calculated based on the time interval between the subject's actual measured tau protein accumulation and a second time (t2) and / or a fourth time (t4).

[0094] For example, if the amount of tau protein accumulation measured in the first region of the subject's brain corresponds to the first accumulation (512) of FIG. 5, the subject's need score can be calculated as the first score (612) by reflecting a predetermined score change amount corresponding to the time interval |t2-t1| to the fourth score (618), which is the score at the second time (t2).

[0095] In another example, if the amount of tau protein accumulation measured in the second region of the subject's brain corresponds to the fifth accumulation (524) of FIG. 5, the subject's efficacy score can be calculated as the sixth score (624) by reflecting a predetermined score change amount corresponding to the time interval |t4-t3| to the eighth score (628), which is the score at the fourth time (t4).

[0096] In one embodiment, based on the calculated need score of the subject, the start time of the golden time for treatment of the subject's Alzheimer's disease can be determined / predicted. Thereafter, based on the determined start time of the golden time for treatment, the remaining time until the start of the golden time for treatment of the subject's Alzheimer's disease can be predicted. For example, if the subject's need score is determined as the first score (612), the current time on the graph (600) is determined as the first time (t1), the start time of the subject's golden time for treatment is determined as the second time (t2), and the remaining time until the start of the subject's golden time for treatment can be predicted as t2-t1.

[0097] In one embodiment, a subject may be identified as likely to respond to an Alzheimer's disease prevention therapy in response to determining that the needs score is less than a predetermined threshold score (e.g., a fourth score (618). In this case, the Alzheimer's disease prevention therapy may include administration of an amyloid (Aβ) vaccine and / or a tau vaccine.

[0098] In one embodiment, based on the calculated efficacy score, the end point of the golden time for treatment of Alzheimer's disease can be determined / predicted. Based on the determined end point of the golden time for treatment, the remaining time until the end of the golden time for treatment of Alzheimer's disease of the subject can be predicted. For example, if the efficacy score of the subject is determined to be the sixth score (624), the current time point on the graph (600) is determined to be the third time point (t3), the end point of the golden time for treatment of the subject is determined to be the fourth time point (t4), and the remaining time until the end of the golden time for treatment of the subject can be predicted to be t4-t3.

[0099] In one embodiment, in response to determining that the efficacy score is less than a predetermined threshold (e.g., score 8 (628)), the subject may be identified as likely to respond to combination therapy comprising amyloid modulating therapy and tau modulating therapy as a treatment for Alzheimer's disease.

[0100] FIG. 7 is a diagram illustrating an example of a predicted value graph (700) of a comprehensive score over time according to one embodiment of the present disclosure. The graph (700) (or the comprehensive score associated with the treatment of the subject's Alzheimer's disease) can be calculated based on the curves (610, 620) (or the first score and the second score) of FIG. 6. For example, the comprehensive score can be calculated by multiplying the subject's first score and the second score at a specific point in time. For example, each of the scores (710, 720, 730, 740, 750) of the graph (700) can be calculated from the product of the necessity score and the efficacy score at each of the first time (t1), the second time (t2), the third time (t3), the fourth time (t4), and the fifth time (t5) of FIG. 6.

[0101] In one embodiment, in response to determining that the subject's composite score is greater than a predetermined threshold (e.g., the second score (720) and / or the fourth score (740)), the subject may be identified as being within the golden time for responding to amyloid modulation therapy as a treatment for Alzheimer's disease.

[0102] FIG. 8 is a flowchart illustrating a method (800) for providing treatment-related prediction information for Alzheimer's disease according to one embodiment of the present disclosure. The method (800) may be performed by at least one processor (e.g., a processor of a user terminal, a processor of an information processing system, or a processor of a device for providing treatment-related prediction information for Alzheimer's disease, etc.). The method (800) may be initiated by the processor receiving a brain scan image of a subject (S810). The subject may be a patient determined to have accumulated beta-amyloid protein (Aβ) in the subject's brain above a predetermined threshold.

[0103] Thereafter, the processor can determine the amount of tau protein accumulation in the first region of the subject's brain based on the scan image (S820).

[0104] Thereafter, the processor may calculate a first score associated with the need for Alzheimer's disease treatment of the subject based on the amount of tau protein accumulation in the first region of the brain of the subject (S830). In one embodiment, the processor may calculate a first time interval between a first time corresponding to the amount of tau protein accumulation in the first region of the brain of the subject and a second time corresponding to a first threshold value of tau protein accumulation on a first path representing a predicted amount of tau protein accumulation in the first region of the brain of the subject over time, and may calculate a first score based on the first time interval. At this time, the first path may be determined based on a data set associated with the amount of tau protein accumulation in the first region of the brain of the subject and each of a plurality of other subjects over time.

[0105] In one embodiment, the processor may identify the subject as likely to respond to an Alzheimer's prevention therapy in response to determining that the first score is less than a predetermined first threshold.

[0106] Thereafter, the processor can determine the amount of tau protein accumulation in a second region of the subject's brain based on the scan image, and calculate a second score associated with the efficacy of Alzheimer's disease treatment for the subject based on the amount of tau protein accumulation in the second region. In one embodiment, the processor can calculate a second time interval between a third time corresponding to the amount of tau protein accumulation in the second region of the subject's brain and a fourth time corresponding to a second threshold value of tau protein accumulation on a second path representing a predicted value of the amount of tau protein accumulation in the second region of the subject over time, and calculate a second score based on the second time interval. In this case, the second path can be determined based on a data set associated with the amount of tau protein accumulation in the second region of the brain over time for each of the subject and a plurality of other subjects.

[0107] The first and second brain regions may be different areas. For example, the first region may be the entorhinal cortex (EC), and the second region may be the inferior temporal gyrus (ITG).

[0108] In one embodiment, the processor can identify the subject as likely to respond to combination therapy comprising amyloid modulation therapy and tau modulation therapy as a treatment for Alzheimer's disease, in response to determining that the second score is less than a predetermined second threshold.

[0109] In one embodiment, the first score may be maintained or increased as the amount of tau protein accumulation in the first region of the subject's brain increases, and the second score may be maintained or decreased as the amount of tau protein accumulation in the second region of the subject's brain increases.

[0110] In one embodiment, the processor may calculate a composite score associated with the treatment of the subject's Alzheimer's disease based on the first and second scores. In response to determining that the composite score is greater than a predetermined third threshold, the processor may identify the subject as being within the golden window for potential response to amyloid-modifying therapy as a treatment for Alzheimer's disease.

[0111] In one embodiment, the processor may determine whether or not to treat or what type of treatment is associated with the subject's Alzheimer's disease based on at least one of the first score, the second score, or the overall score.

[0112] In one embodiment, the processor can determine the start time of the golden time for treating Alzheimer's disease of the subject based on the first score, and can predict the time remaining until the start time of the golden time for treating Alzheimer's disease of the subject based on the determined start time of the golden time for treating Alzheimer's disease.

[0113] In one embodiment, the processor can determine the end point of the golden time for treating Alzheimer's disease based on the second score, and can predict the time remaining until the end point of the golden time for treating Alzheimer's disease of the subject based on the determined end point of the golden time for treating Alzheimer's disease.

[0114] The flowchart illustrated in Figure 8 and the description above are merely examples, and some embodiments may be implemented differently. For example, one or more steps may be omitted, the order of each step may be changed, one or more steps may be performed in an overlapping manner, or one or more steps may be repeated multiple times.

[0115] The above-described method may be provided as a computer program stored on a computer-readable recording medium for execution on a computer. The medium may be one that continuously stores a computer-executable program or one that temporarily stores it for execution or download. In addition, the medium may be various recording or storage means in the form of a single or multiple hardware combinations, and is not limited to a medium directly connected to a computer system, but may also be distributed over a network. Examples of the medium may include magnetic media such as hard disks, floppy disks, and magnetic tapes, optical recording media such as CD-ROMs and DVDs, magneto-optical media such as floptical disks, and those configured to store program instructions, including ROM, RAM, and flash memory. In addition, examples of other media may include recording or storage media managed by app stores that distribute applications, sites that supply or distribute various software, servers, etc.

[0116] The methods, operations, or techniques of the present disclosure may be implemented by various means. For example, these techniques may be implemented in hardware, firmware, software, or a combination thereof. Those skilled in the art will appreciate that the various exemplary logical blocks, modules, circuits, and algorithm steps described in connection with the disclosure herein may be implemented as electronic hardware, computer software, or a combination of both. To clearly illustrate this interchangeability of hardware and software, various exemplary components, blocks, modules, circuits, and steps have been described above generally in terms of their functionality. Whether such functionality is implemented as hardware or software depends on the particular application and the design requirements imposed on the overall system. Those skilled in the art may implement the described functionality in various ways for each particular application, but such implementations should not be construed as departing from the scope of the present disclosure.

[0117] In a hardware implementation, the processing units used to perform the techniques may be implemented within one or more ASICs, DSPs, digital signal processing devices (DSPDs), programmable logic devices (PLDs), field programmable gate arrays (FPGAs), processors, controllers, microcontrollers, microprocessors, electronic devices, other electronic units designed to perform the functions described herein, a computer, or a combination thereof.

[0118] Accordingly, the various exemplary logical blocks, modules, and circuits described in connection with the present disclosure may be implemented or performed by any combination of a general-purpose processor, a DSP, an ASIC, an FPGA or other programmable logic device, discrete gate or transistor logic, discrete hardware components, or those designed to perform the functions described herein. A general-purpose processor may be a microprocessor, but in the alternative, the processor may be any conventional processor, controller, microcontroller, or state machine. A processor may also be implemented as a combination of computing devices, e.g., a combination of a DSP and a microprocessor, a plurality of microprocessors, one or more microprocessors in conjunction with a DSP core, or any other such configuration.

[0119] In a firmware and / or software implementation, the techniques may be implemented as instructions stored on a computer-readable medium, such as random access memory (RAM), read-only memory (ROM), non-volatile random access memory (NVRAM), programmable read-only memory (PROM), erasable programmable read-only memory (EPROM), electrically erasable PROM (EEPROM), flash memory, a compact disc (CD), a magnetic or optical data storage device, etc. The instructions may be executable by one or more processors and may cause the processor(s) to perform certain aspects of the functionality described herein.

[0120] While the embodiments described above have been described as utilizing aspects of the presently disclosed subject matter in one or more standalone computer systems, the present disclosure is not limited thereto and may be implemented in conjunction with any computing environment, such as a network or distributed computing environment. Furthermore, aspects of the present disclosure may be implemented in multiple processing chips or devices, and storage may be similarly affected across multiple devices. Such devices may include personal computers, network servers, and portable devices.

[0121] While the present disclosure has been described in connection with certain embodiments herein, various modifications and variations may be made without departing from the scope of the present disclosure, which would be apparent to those skilled in the art. Furthermore, such modifications and variations are intended to fall within the scope of the claims appended to this specification.

Claims

1. A method for providing prediction information related to treatment of Alzheimer's disease, which is executed by at least one processor, A step of receiving a brain scan image of a subject; A step of determining the amount of tau protein accumulation in the first region of the subject's brain based on the scan image; and A step of calculating a first score associated with the need for Alzheimer's disease treatment of the subject based on the amount of tau protein accumulation in the first region of the subject's brain. A method for providing predictive information related to treatment of Alzheimer's disease, including:

2. In paragraph 1, A step of determining the amount of tau protein accumulation in the second region of the subject's brain based on the scan image; and A step of calculating a second score associated with the efficacy of Alzheimer's disease treatment for the subject based on the amount of tau protein accumulation in the second region. Including more, A method for providing predictive information related to treatment of Alzheimer's disease, wherein the first region and the second region are different regions.

3. In paragraph 2, The above first score is, As the amount of tau protein accumulation in the first area of ​​the brain of the subject increases, it is maintained or increases, The above second score is, A method for providing predictive information related to the treatment of Alzheimer's disease, wherein the amount of tau protein accumulation in the second region of the brain of the subject is maintained or decreased as the amount increases.

4. In paragraph 2, A step of calculating a comprehensive score associated with the treatment of Alzheimer's disease of the subject based on the first score and the second score. A method for providing predictive information related to treatment of Alzheimer's disease, further comprising:

5. In paragraph 4, A step of determining whether to treat or what type of treatment is required for the subject's Alzheimer's disease based on at least one of the first score, the second score, or the overall score. A method for providing predictive information related to treatment of Alzheimer's disease, further comprising:

6. In paragraph 1, A step of estimating the starting point of the golden time for treatment of Alzheimer's disease of the subject based on the first score above. A method for providing predictive information related to treatment of Alzheimer's disease, further comprising:

7. In paragraph 6, A step of predicting the time remaining until the start of the golden time for treatment of Alzheimer's disease of the subject based on the start time of the golden time for treatment determined above. A method for providing predictive information related to treatment of Alzheimer's disease, further comprising:

8. In paragraph 1, The step of calculating the above first score is: A step of calculating a first time interval between a first time corresponding to the tau protein accumulation amount in the first region of the subject's brain and a second time at which the tau protein accumulation amount is a predetermined first threshold value, on a first path representing a predicted value of the tau protein accumulation amount in the first region according to time change; and A step of calculating the first score based on the first time interval A method for providing predictive information related to treatment of Alzheimer's disease, including:

9. In paragraph 8, The above first path is, A method for providing predictive information related to treatment of Alzheimer's disease, determined based on a data set associated with the amount of tau protein accumulation in a first region of the brain over time for each of the above subject and a plurality of other subjects.

10. In paragraph 2, A step of determining the end point of the golden time for treatment of Alzheimer's disease based on the second score above. A method for providing predictive information related to treatment of Alzheimer's disease, further comprising:

11. In paragraph 10, A step of predicting the time remaining until the end of the treatment golden time for the subject's Alzheimer's disease based on the end point of the above-determined treatment golden time. A method for providing predictive information related to treatment of Alzheimer's disease, further comprising:

12. In paragraph 2, The step of calculating the second score is: A step of calculating a second time interval between a third time corresponding to the amount of tau protein accumulated in the second region of the subject's brain and a fourth time corresponding to a second threshold value of tau protein accumulated on a second path representing a predicted amount of tau protein accumulated in the second region according to time change; and A step of calculating the second score based on the second time interval A method for providing predictive information related to treatment of Alzheimer's disease, including:

13. In paragraph 12, The second path above is, A method for providing predictive information related to treatment of Alzheimer's disease, determined based on a data set associated with the amount of tau protein accumulation in a second region of the brain over time for each of the above-mentioned subject and a plurality of other subjects.

14. In paragraph 1, A method for providing predictive information related to treatment of Alzheimer's disease, wherein the subject is a patient who is determined to have accumulated beta-amyloid protein (Aβ) exceeding a predetermined threshold in the subject's brain.

15. In paragraph 1, A method for providing predictive information related to treatment of Alzheimer's disease, wherein the first region is the entorhinal cortex (EC) region.

16. In paragraph 2, A method for providing predictive information related to treatment of Alzheimer's disease, wherein the second region is the inferior temporal gyrus (ITG) region.

17. In paragraph 4, In response to determining that the above comprehensive score is greater than a predetermined third threshold, a step of identifying the subject as being within the golden time in which the subject is likely to respond to amyloid modulation treatment as an Alzheimer's treatment. A method for providing predictive information related to treatment of Alzheimer's disease, further comprising:

18. In paragraph 1, In response to determining that the first score is less than a predetermined first threshold, a step of identifying the subject as likely to respond to Alzheimer's prevention therapy. A method for providing predictive information related to treatment of Alzheimer's disease, further comprising:

19. In paragraph 2, In response to determining that the second score is less than a predetermined second threshold, a step of identifying the subject as likely to respond to combination treatment including amyloid modulation treatment and tau modulation treatment as an Alzheimer's treatment. A method for providing predictive information related to treatment of Alzheimer's disease, further comprising:

20. A computer program stored on a computer-readable recording medium for executing the method according to any one of claims 1 to 19 on a computer.

21. In the device, Communication module; memory; and At least one processor connected to said memory and configured to execute at least one computer-readable program contained in said memory Including, At least one program above, Receive brain scan images of the subject, Based on the above scan image, the amount of tau protein accumulation in the first region of the subject's brain is determined, A device comprising instructions for calculating a first score associated with a need for Alzheimer's disease treatment of the subject based on the amount of tau protein accumulation in a first region of the brain of the subject.

Citation Information

Patent Citations

  • Data processing method and system for predicting performance of industrial facilities

    KR1020240158063A

  • Method for emphasizing analyte values during a therapeutic window

    US20190239780A1

  • System, software and methods of using software for predicting efficacy of alzheimer's disease treatments

    WO2022072738A1